ASCO 2024 | RxPONDER: chemotherapy and endocrine therapy in HR+/HER2- breast cancer

Kevin Kalinsky • 2 Jun 2024

ASCO 2024

Breast Cancer

RxPONDER

Kevin Kalinsky, MD, MS, Winship Cancer Institute, Atlanta, GA, gives an overview of the Phase III RxPONDER trial (NCT01272037), which investigated the benefit of adding chemotherapy to endocrine therapy (ET) in premenopausal women with HR+/HER2- invasive breast cancer and a recurrence score (RS) ≤ 25. Baseline levels of anti-Müllerian hormone (AMH) significantly predicted the benefit of chemotherapy, while other hormone levels did not, highlighting AMH as a valuable marker for guiding adjuvant chemotherapy decisions. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – EQRx (I); GRAIL (I)
Stock and Other Ownership Interests – EQRx (I); GRAIL (I)
Consulting or Advisory Role – 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding – Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship – Genentech; Immunomedics